First-in-Class Oral Antibiotic Nuzolvence Approved For Gonorrhea
▫️The Food And Drug Administration (FDA) Has Approved Nuzolvence® (Zoliflodacin For Oral Suspension) For The Treatment of Uncomplicated Urogenital Gonorrhea in Adults And Children Aged 12 Years And Older Weighing at Least 35kg.
▫️Zoliflodacin Is An Oral Spiropyrimidinetrione Antibiotic With Activity Against Multidrug-Resistant Strains of Neisseria Gonorrhoeae, Including Those Resistant to Ceftriaxone And Azithromycin (In-Vitro Studies).
@MedicalNewsToday
▫️The Food And Drug Administration (FDA) Has Approved Nuzolvence® (Zoliflodacin For Oral Suspension) For The Treatment of Uncomplicated Urogenital Gonorrhea in Adults And Children Aged 12 Years And Older Weighing at Least 35kg.
▫️Zoliflodacin Is An Oral Spiropyrimidinetrione Antibiotic With Activity Against Multidrug-Resistant Strains of Neisseria Gonorrhoeae, Including Those Resistant to Ceftriaxone And Azithromycin (In-Vitro Studies).
@MedicalNewsToday
👌4
Children’s Hospital Colorado Completes Its First Heart And Liver Dual Transplant
▫️Children's Hospital Colorado (Children's Colorado) Successfully Performed The Hospital's First-Ever Heart And Liver Dual Organ Transplant, With Support From Dozens of Team Members Across 25 Different Multidisciplinary Care Teams. Only 38 Other Pediatric Heart And Liver Dual Organ Transplants Have Been Completed in The United States.
@MedicalNewsToday
▫️Children's Hospital Colorado (Children's Colorado) Successfully Performed The Hospital's First-Ever Heart And Liver Dual Organ Transplant, With Support From Dozens of Team Members Across 25 Different Multidisciplinary Care Teams. Only 38 Other Pediatric Heart And Liver Dual Organ Transplants Have Been Completed in The United States.
@MedicalNewsToday
👌4
Berotralstat Becomes First Oral Prophylactic For Pediatric Patients With Hereditary Angioedema
▫️The US Food And Drug Administration (FDA) Has Approved The New Drug Application For An Oral Pellet Formulation of Berotralstat (Orladeyo; BioCryst), A Once-Daily Prophylactic Plasma Kallikrein Inhibitor, For Pediatric Patients Aged 2 Through Less Than 12 Years With Hereditary Angioedema (HAE), According to A News Release From BioCryst.
▫️HAE Often Presents During Childhood, With Approximately 40% of Children Experiencing Their First Attack by The Age of 5 Years. The Rare Genetic Condition Presents As Localized Swelling of Tissues Underneath The Skin And Can Be Accompanied by Signs of An Allergic Reaction.
@MedicalNewsToday
▫️The US Food And Drug Administration (FDA) Has Approved The New Drug Application For An Oral Pellet Formulation of Berotralstat (Orladeyo; BioCryst), A Once-Daily Prophylactic Plasma Kallikrein Inhibitor, For Pediatric Patients Aged 2 Through Less Than 12 Years With Hereditary Angioedema (HAE), According to A News Release From BioCryst.
▫️HAE Often Presents During Childhood, With Approximately 40% of Children Experiencing Their First Attack by The Age of 5 Years. The Rare Genetic Condition Presents As Localized Swelling of Tissues Underneath The Skin And Can Be Accompanied by Signs of An Allergic Reaction.
@MedicalNewsToday
👌4
Early Peanut Introduction Can Prevent Allergy But Parents Need Clearer Guidance
▫️Feeding Babies Peanut-Containing Foods As Early As Possible Can Help Prevent Peanut Allergy, But A New Study Published in JAMA Network Open Found That Parents Need More Support to Get It Right.
@MedicalNewsToday
▫️Feeding Babies Peanut-Containing Foods As Early As Possible Can Help Prevent Peanut Allergy, But A New Study Published in JAMA Network Open Found That Parents Need More Support to Get It Right.
@MedicalNewsToday
❤4
FDA Approved Rucaparib For The Treatment of Adults With mCRPC
▫️The US Food And Drug Administration (FDA) Has Approved Rucaparib (Rubraca; Pharmaand GmbH) For The Treatment of Adult Patients With A Deleterious BRCA Mutation Associated Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With An Androgen Receptor-Directed Therapy.
▫️The Recommended dose For Rucaparib Is 600 mg (Two 300 mg Tablets) Taken Orally Twice Per Day With or Without Food, For A Total Daily dose of 1200 mg Until Disease Progression or Unacceptable Toxicity.
@MedicalNewsToday
▫️The US Food And Drug Administration (FDA) Has Approved Rucaparib (Rubraca; Pharmaand GmbH) For The Treatment of Adult Patients With A Deleterious BRCA Mutation Associated Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With An Androgen Receptor-Directed Therapy.
▫️The Recommended dose For Rucaparib Is 600 mg (Two 300 mg Tablets) Taken Orally Twice Per Day With or Without Food, For A Total Daily dose of 1200 mg Until Disease Progression or Unacceptable Toxicity.
@MedicalNewsToday
❤4
Ultra-Processed Foods Linked to Higher Mortality in Black Women With Breast Cancer
▫️A Study From Rutgers Cancer Institute Researchers in eClinicalMedicine Is The First to Link Ultra-Processed Foods to Reduced Survival in Black Women With Breast Cancer.
▫️Black Patients With Breast Cancer Who Ate The Most Ultra-Processed Foods Before Diagnosis Were 36-40% More Likely to Die From Their Cancers or Other Causes of Death Than Those Who Ate The Fewest Ultra-Processed Foods.
@MedicalNewsToday
▫️A Study From Rutgers Cancer Institute Researchers in eClinicalMedicine Is The First to Link Ultra-Processed Foods to Reduced Survival in Black Women With Breast Cancer.
▫️Black Patients With Breast Cancer Who Ate The Most Ultra-Processed Foods Before Diagnosis Were 36-40% More Likely to Die From Their Cancers or Other Causes of Death Than Those Who Ate The Fewest Ultra-Processed Foods.
@MedicalNewsToday
❤4
HPV Vaccination Reduces Risk of Vulvar And Vaginal Lesions
▫️Girls Who Are Vaccinated Against HPV Are Not Only Well Protected Against Cervical Cancer; They Are Also Less Likely to Develop Severe Precancerous Lesions of The Vulva And Vagina, Particularly If They Were Vaccinated Before The Age of 17.
▫️This Is Shown In A New Study From Karolinska Institutet Published in JAMA Oncology.
@MedicalNewsToday
▫️Girls Who Are Vaccinated Against HPV Are Not Only Well Protected Against Cervical Cancer; They Are Also Less Likely to Develop Severe Precancerous Lesions of The Vulva And Vagina, Particularly If They Were Vaccinated Before The Age of 17.
▫️This Is Shown In A New Study From Karolinska Institutet Published in JAMA Oncology.
@MedicalNewsToday
👌4
Platelet-Rich Plasma Shows Potential for Hair Growth in Breast Cancer Survivors
▫️In A Pilot Study of Breast Cancer Survivors With Endocrine-Induced Alopecia (EIA) or Persistent Chemotherapy-Induced Alopecia (pCIA), Platelet-Rich Plasma (PRP) Treatment Increased Hair Density, With Improvements Observed On Both Treated And Untreated Scalp Areas, Likely Due to PRP Diffusion.
▫️This Study Was Published Online in Dermatologic Surgery.
@MedicalNewsToday
▫️In A Pilot Study of Breast Cancer Survivors With Endocrine-Induced Alopecia (EIA) or Persistent Chemotherapy-Induced Alopecia (pCIA), Platelet-Rich Plasma (PRP) Treatment Increased Hair Density, With Improvements Observed On Both Treated And Untreated Scalp Areas, Likely Due to PRP Diffusion.
▫️This Study Was Published Online in Dermatologic Surgery.
@MedicalNewsToday
FDA Expands Flibanserin Approval to Postmenopausal Women With Hypoactive Sexual Desire Disorder
▫️Flibanserin (Addyi), The Drug Manufactured by Sprout Pharmaceuticals For The Treatment of Hypoactive Sexual Desire Disorder (HSDD), Received Approval From The FDA For Use in Postmenopausal Women Up to Age 64 Last Week.
▫️The Medication Was First Approved A Decade Ago For Premenopausal Women, But No FDA-Approved Pharmacologic Options Have Been Available to Postmenopausal Women Until Now.
▫️HSDD, Which Refers to A Persistent or Recurring Loss of Desire For Sexual Activity That Contributes to Personal or Interpersonal Distress, Is Estimated to Affect 1 in 10 US Women.
@MedicalNewsToday
▫️Flibanserin (Addyi), The Drug Manufactured by Sprout Pharmaceuticals For The Treatment of Hypoactive Sexual Desire Disorder (HSDD), Received Approval From The FDA For Use in Postmenopausal Women Up to Age 64 Last Week.
▫️The Medication Was First Approved A Decade Ago For Premenopausal Women, But No FDA-Approved Pharmacologic Options Have Been Available to Postmenopausal Women Until Now.
▫️HSDD, Which Refers to A Persistent or Recurring Loss of Desire For Sexual Activity That Contributes to Personal or Interpersonal Distress, Is Estimated to Affect 1 in 10 US Women.
@MedicalNewsToday
FDA Approved Meningioma Label Warning on Pfizer’s Contraceptive Injection
▫️The US Food And Drug Administration (FDA) Has Approved A Label Change to Pfizer’s Injectable Contraceptive, Depo-Provera (Medroxyprogesterone Acetate), Which Will Warn Users of Their Increased Risk of Meningioma.
▫️The FDA’s Crackdown On Depo-Provera Comes Amid A Highly Publicised Legal Battle Between Pfizer And More Than 2,000 Women, Who Are Currently Suing The New York-Based Pharma After They Developed Meningiomas They Believe Are Caused by Exposure to The Contraceptive.
▫️Depo-Provera Contains Progestin, A Synthetic Form of The Sex Hormone Progesterone. While It Has Been On The Contraceptive Market Since The Early 1990s, A Recent Study Published in The British Medical Journal Has Uncovered The Heightened Risk of Intracranial Meningioma Associated With The Jab’s Prolonged Use.
@MedicalNewsToday
▫️The US Food And Drug Administration (FDA) Has Approved A Label Change to Pfizer’s Injectable Contraceptive, Depo-Provera (Medroxyprogesterone Acetate), Which Will Warn Users of Their Increased Risk of Meningioma.
▫️The FDA’s Crackdown On Depo-Provera Comes Amid A Highly Publicised Legal Battle Between Pfizer And More Than 2,000 Women, Who Are Currently Suing The New York-Based Pharma After They Developed Meningiomas They Believe Are Caused by Exposure to The Contraceptive.
▫️Depo-Provera Contains Progestin, A Synthetic Form of The Sex Hormone Progesterone. While It Has Been On The Contraceptive Market Since The Early 1990s, A Recent Study Published in The British Medical Journal Has Uncovered The Heightened Risk of Intracranial Meningioma Associated With The Jab’s Prolonged Use.
@MedicalNewsToday
Novo Nordisk’s Weight Loss Pill Approved by FDA
▫️The FDA Has Approved Once-Daily Oral Semaglutide 25 mg (Wegovy Pill, Novo Nordisk) As The First GLP-1 Agonist Pill For Weight Management.
▫️The New Indication Is “to Reduce Excess Body Weight And Maintain Weight Reduction Long Term And to Reduce The Risk of Major Adverse Cardiovascular Events,” Novo Nordisk Announced in A December 22, 2025, Statement.
▫️The Wegovy Pill Is A Higher dose of The Oral Semaglutide Rybelsus (7 mg And 14 mg), FDA-Approved in 2019 For Treating Type 2 Diabetes (T2D) And in October 2025 For Cardiovascular Risk Reduction in Those With T2D at High Risk.
▫️The Market Is Currently Dominated by Weekly Injections That Can Spur Significant Weight Loss. The Pill Forms of Those Drugs Appear to Be Somewhat Less Potent, But Are More Convenient to Take And Could Substantially Broaden Use.
@MedicalNewsToday
▫️The FDA Has Approved Once-Daily Oral Semaglutide 25 mg (Wegovy Pill, Novo Nordisk) As The First GLP-1 Agonist Pill For Weight Management.
▫️The New Indication Is “to Reduce Excess Body Weight And Maintain Weight Reduction Long Term And to Reduce The Risk of Major Adverse Cardiovascular Events,” Novo Nordisk Announced in A December 22, 2025, Statement.
▫️The Wegovy Pill Is A Higher dose of The Oral Semaglutide Rybelsus (7 mg And 14 mg), FDA-Approved in 2019 For Treating Type 2 Diabetes (T2D) And in October 2025 For Cardiovascular Risk Reduction in Those With T2D at High Risk.
▫️The Market Is Currently Dominated by Weekly Injections That Can Spur Significant Weight Loss. The Pill Forms of Those Drugs Appear to Be Somewhat Less Potent, But Are More Convenient to Take And Could Substantially Broaden Use.
@MedicalNewsToday
Scientists Found A Way to Restore Brain Blood Flow in Dementia
▫️A New Study Suggests That Dementia May Be Driven in Part by Faulty Blood Flow in The Brain. Researchers Found That Losing A Key Lipid Causes Blood Vessels to Become Overactive, Disrupting Circulation And Starving Brain Tissue.
▫️Their Preclinical Research, Published December 22 in Proceedings of The National Academy of Sciences, Suggests That Replacing A Missing Phospholipid in The Bloodstream Could Help Restore Normal Brain Blood Flow And Ease Dementia-Related Symptoms.
@MedicalNewsToday
▫️A New Study Suggests That Dementia May Be Driven in Part by Faulty Blood Flow in The Brain. Researchers Found That Losing A Key Lipid Causes Blood Vessels to Become Overactive, Disrupting Circulation And Starving Brain Tissue.
▫️Their Preclinical Research, Published December 22 in Proceedings of The National Academy of Sciences, Suggests That Replacing A Missing Phospholipid in The Bloodstream Could Help Restore Normal Brain Blood Flow And Ease Dementia-Related Symptoms.
@MedicalNewsToday
This Popular Painkiller May Do More Harm Than Good
▫️A Large Review of Existing Research Suggests That Tramadol, A Strong Opioid Commonly Prescribed For Chronic Pain, Does Not Provide Much Meaningful Relief.
▫️The Analysis Published Online in BMJ Evidence Based Medicine, Found That While Tramadol Can Reduce Pain, The Improvement Is Modest And Falls Below Levels Typically Considered Clinically Important.
@MedicalNewsToday
▫️A Large Review of Existing Research Suggests That Tramadol, A Strong Opioid Commonly Prescribed For Chronic Pain, Does Not Provide Much Meaningful Relief.
▫️The Analysis Published Online in BMJ Evidence Based Medicine, Found That While Tramadol Can Reduce Pain, The Improvement Is Modest And Falls Below Levels Typically Considered Clinically Important.
@MedicalNewsToday
FDA Approved Omeros’ Yartemlea For Stem Cell Patients
▫️The US Food And Drug Administration (FDA) Has Approved Omeros' Yartemlea (Narsoplimab) As The First Treatment For Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA), An Often-Fatal Complication of Stem-Cell Transplantation Driven by Activation of The Lectin Pathway of Complement.
▫️Yartemlea Is The First And Only Approved Lectin Pathway Inhibitor. Yartemlea Selectively Inhibits MASP-2, The Effector Enzyme of The Lectin Pathway, Blocking Pathway Activation While Preserving Classical And Alternative Complement Functions Important For Host Defense.
▫️Yartemlea Is Approved For Use in Adults And in Children Ages Two Years And Older.
@MedicalNewsToday
▫️The US Food And Drug Administration (FDA) Has Approved Omeros' Yartemlea (Narsoplimab) As The First Treatment For Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA), An Often-Fatal Complication of Stem-Cell Transplantation Driven by Activation of The Lectin Pathway of Complement.
▫️Yartemlea Is The First And Only Approved Lectin Pathway Inhibitor. Yartemlea Selectively Inhibits MASP-2, The Effector Enzyme of The Lectin Pathway, Blocking Pathway Activation While Preserving Classical And Alternative Complement Functions Important For Host Defense.
▫️Yartemlea Is Approved For Use in Adults And in Children Ages Two Years And Older.
@MedicalNewsToday
Women May Derive Greater Long-Term Benefits From Coronary Artery Bypass Grafting Compared With Stents
▫️Women With Severe Coronary Heart Disease Causing Narrowing or Blockages in The Arteries May Derive Greater Long-Term Benefits From Coronary Artery Bypass Grafting Compared With Percutaneous Coronary Intervention, Also Known As Stenting, According to A Large Study by Weill Cornell Medicine Investigators.
▫️The Study, Published Nov. 25 in The European Heart Journal.
@MedicalNewsToday
▫️Women With Severe Coronary Heart Disease Causing Narrowing or Blockages in The Arteries May Derive Greater Long-Term Benefits From Coronary Artery Bypass Grafting Compared With Percutaneous Coronary Intervention, Also Known As Stenting, According to A Large Study by Weill Cornell Medicine Investigators.
▫️The Study, Published Nov. 25 in The European Heart Journal.
@MedicalNewsToday
Etripamil Becomes First, Only Self-Administered Nasal Spray Approved For PSVT
▫️The US Food And Drug Administration (FDA) Has Approved Etripamil (Cardamyst; Milestone Pharmaceuticals), The First And Only Self-Administered Nasal Spray For Adults For The Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm, According to A News Release From Milestone Pharmaceuticals.
▫️PSVT Is A Form of Arrhythmia That Occurs When A Short-Circuit Rhythm Develops in The Upper Chamber of The Heart, Resulting in A Rapid Heartbeat That Can Start And Stop Abruptly. It Can Impair A Patient’s Heart Function, Leading to Symptoms Like Shortness of Breath or Lightheadedness.
@MedicalNewsToday
▫️The US Food And Drug Administration (FDA) Has Approved Etripamil (Cardamyst; Milestone Pharmaceuticals), The First And Only Self-Administered Nasal Spray For Adults For The Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm, According to A News Release From Milestone Pharmaceuticals.
▫️PSVT Is A Form of Arrhythmia That Occurs When A Short-Circuit Rhythm Develops in The Upper Chamber of The Heart, Resulting in A Rapid Heartbeat That Can Start And Stop Abruptly. It Can Impair A Patient’s Heart Function, Leading to Symptoms Like Shortness of Breath or Lightheadedness.
@MedicalNewsToday
Sanofi’s Wayrilz Wins Approval in The EU
▫️The European Commission Has Approved Wayrilz (Rilzabrutinib), A Novel, Oral, Reversible, Bruton’s Tyrosine Kinase (BTK) Inhibitor, As A New Treatment For Immune Thrombocytopenia (ITP) in Adult Patients Who Are Refractory to Other Treatments.
▫️This Follows The Positive Opinion by The European Medicines Agency's Human Medicines Advisory Committee, The CHMP.
▫️According to Its Developer, French Pharma Major Sanofi, Wayrilz Can Help Address The Underlying Causes of ITP Through Multi-Immune Modulation, Targeting Different Pathways Across The Immune System.
@MedicalNewsToday
▫️The European Commission Has Approved Wayrilz (Rilzabrutinib), A Novel, Oral, Reversible, Bruton’s Tyrosine Kinase (BTK) Inhibitor, As A New Treatment For Immune Thrombocytopenia (ITP) in Adult Patients Who Are Refractory to Other Treatments.
▫️This Follows The Positive Opinion by The European Medicines Agency's Human Medicines Advisory Committee, The CHMP.
▫️According to Its Developer, French Pharma Major Sanofi, Wayrilz Can Help Address The Underlying Causes of ITP Through Multi-Immune Modulation, Targeting Different Pathways Across The Immune System.
@MedicalNewsToday
Eating More Vitamin C Can Physically Change Your Skin
▫️Scientists Discovered That Vitamin C From Food Travels Through The Bloodstream Into Every Layer of The Skin, Boosting Collagen And Skin Renewal. People Who Ate Two Vitamin C–Packed Kiwifruit Daily Showed Thicker, Healthier Skin.
▫️Published in The Journal of Investigative Dermatology, The Research Found That Vitamin C Levels in The Skin Closely Mirror Levels in The Blood (Plasma). Increasing Intake Through Vitamin C Rich Foods Was Shown to Raise Both Blood And Skin Concentrations.
@MedicalNewsToday
▫️Scientists Discovered That Vitamin C From Food Travels Through The Bloodstream Into Every Layer of The Skin, Boosting Collagen And Skin Renewal. People Who Ate Two Vitamin C–Packed Kiwifruit Daily Showed Thicker, Healthier Skin.
▫️Published in The Journal of Investigative Dermatology, The Research Found That Vitamin C Levels in The Skin Closely Mirror Levels in The Blood (Plasma). Increasing Intake Through Vitamin C Rich Foods Was Shown to Raise Both Blood And Skin Concentrations.
@MedicalNewsToday
Enhertu Combo Wins FDA Approval For First-Line Use in HER2+ Metastatic Breast Cancer
▫️AstraZeneca and Daiichi Sankyo’s Enhertu, in Combination With Roche’s Perjeta (Pertuzumab), Has Been Approved by The US FDA to Treat Adult Patients With Unresectable or Metastatic HER2-Positive Breast Cancer.
▫️The Agency Originally Endorsed Perjeta, A Targeted Monoclonal Antibody, in 2012 in Combination With Roche’s Herceptin And Chemotherapy As A First-Line Treatment For Those With HER2-Positive Metastatic Breast Cancer.
▫️The US Regulator Has Signed off On Enhertu Combined With Roche’s Perjeta As A First-Line Treatment For Unresectable or Metastatic HER2-Positive Breast Cancer As Confirmed by An FDA-Approved Test.
▫️The Data For The Drug’s Latest Approval Were Presented at The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting And Published in The New England Journal of Medicine.
@MedicalNewsToday
▫️AstraZeneca and Daiichi Sankyo’s Enhertu, in Combination With Roche’s Perjeta (Pertuzumab), Has Been Approved by The US FDA to Treat Adult Patients With Unresectable or Metastatic HER2-Positive Breast Cancer.
▫️The Agency Originally Endorsed Perjeta, A Targeted Monoclonal Antibody, in 2012 in Combination With Roche’s Herceptin And Chemotherapy As A First-Line Treatment For Those With HER2-Positive Metastatic Breast Cancer.
▫️The US Regulator Has Signed off On Enhertu Combined With Roche’s Perjeta As A First-Line Treatment For Unresectable or Metastatic HER2-Positive Breast Cancer As Confirmed by An FDA-Approved Test.
▫️The Data For The Drug’s Latest Approval Were Presented at The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting And Published in The New England Journal of Medicine.
@MedicalNewsToday
FDA Approved First Pill For Treating Anemia in Adults With Alpha- or Beta- Thalassemia
▫️The Food and Drug Administration (FDA) Has Approved Aqvesme™ (Mitapivat) For The Treatment of Anemia in Adults With Alpha- or Beta-Thalassemia.
▫️Aqvesme Is The Only FDA-Approved Medicine For Both Non-Transfusion Dependent And Transfusion-Dependent Thalassemia.
▫️Aqvesme Comes As A Tablet You Take Twice Daily, With or Without Food. Swallow Tablets Whole Without Splitting, Crushing, Chewing, or Dissolving Them.
@MedicalNewsToday
▫️The Food and Drug Administration (FDA) Has Approved Aqvesme™ (Mitapivat) For The Treatment of Anemia in Adults With Alpha- or Beta-Thalassemia.
▫️Aqvesme Is The Only FDA-Approved Medicine For Both Non-Transfusion Dependent And Transfusion-Dependent Thalassemia.
▫️Aqvesme Comes As A Tablet You Take Twice Daily, With or Without Food. Swallow Tablets Whole Without Splitting, Crushing, Chewing, or Dissolving Them.
@MedicalNewsToday